Neurology News

CuraSen Therapeutics Inc. announced it has begun dosing patients in a phase 2a clinical trial with CST-2032, an oral therapeutic for treatment of mild cognitive impairment or mild dementia due to either Parkinson’s or Alzheimer’s disease.

Cedars-Sinai’s department of computational biomedicine has been awarded an $8 million NIH grant to use artificial intelligence methods to identify genetic predictors of Alzheimer's disease.

The FDA granted accelerated approval to bluebird bio Inc for elivaldogene autotemcel, its gene therapy that aims to slow progression of neurologic dysfunction in boys aged 4 to 17 with early, active cerebral adrenoleukodystrophy, or CALD.

Headache disorders in American veterans were higher for men than women in incidence related to trauma, but men had fewer encounters for headaches and fewer visits to headache specialists, according to a study published in Neurology.

Results of a recently released poll revealed that roughly 60% of patients with Parkinson’s disease do not believe their symptoms are manageable and cannot be improved beyond their current state.

The FDA has accepted a new drug application from Acadia Pharmaceuticals Inc. for trofinetide, a synthetic analog of the amino‐terminal tripeptide of IGF-1 designed to treat core symptoms of Rett syndrome.

In this edition, new cannabinoids hold promise for medical applications; Theranica secures $45 million for migraine treatment device and more.

Revitalist Lifestyle and Wellness and Wake Network Inc. announced a joint venture to offer ketamine infusions in the U.S. and psilocybin clinical retreats internationally with a special focus on military veterans’ need for access.

LAS VEGAS — Chronic pain is not a straightforward disease, and the clinician must gather information from a variety of sources, a presenter said at PAINWeek 2022.

LAS VEGAS — CDC guidelines issued in response to the opioid crisis have led to many health care providers reducing or eliminating pain control with opioids, Paul J. Christo, MD, MBA, said at PAINWeek 2022.